Health ❯ Healthcare ❯ Research
Phase 3 Trials Efficacy Studies Trial Results Cancer Research Trial Outcomes Trial Methodology AI in Medicine Gene Therapy Trials Innovative Therapies Animal Studies Pediatric COVID-19 Studies Human Trials Neurodegenerative Diseases Systematic Reviews Exercise and Cancer Neuroscience ASH Annual Meeting Patient Advocacy Phase 1 Trials Long-term Outcomes Patient Outcomes Pain Therapies Monoclonal Antibodies for Covid-19 Patient Studies KARDIA-2 Study Drug Development Drug Approval Process Innovation Strategies Collaboration in Medicine Outcomes Research Translational Pathology Genetic Research Alzheimer's Drug Trials FRONTIER2 Trial Biomarkers in Neurology Mass General Brigham University-Hospital Collaboration Patient Care Data Integration OHSU Genetic Counseling Disease Modification Pediatric NeuroRecovery Gastroenterology Rare Diseases Stroke Rehabilitation Research Neurological Research GINECO Group Caries Detection Neuroscience Studies Phase 2 Trials Pediatric Research Gastroparesis Research Translational Research Cardiovascular Clinical Research LiBBY Trial Innovation in Medicine Therapeutics Post-COVID-19 Research Grant Funding Literature Review Treatment Paradigms Rare Disease Research Cancer Immunotherapy Tick-Borne Diseases Phase 3 Studies Gene Therapy
Want to see what podcasts are saying about this topic? Search across 135K+ podcasts. Explore Radar
Investigators say the one-year remission shows that TCR‑engineered cells targeting an intracellular antigen can clear some solid tumors, prompting a planned Phase I/II pediatric trial in 2027.
